An official website of the United States government
Primary Products
Beginning with cases diagnosed in January 1, 2024 and forward, the Cancer PathCHART initiative standards included in the Cancer PathCHART ICD-O-3 Site Morphology Validation Lists (CPC SMVLs) should be used.
- These lists designate all tumor site-morphology combinations that are either valid or impossible as determined for the sites reviewed by the Cancer PathCHART initiative.
- For sites not yet reviewed by Cancer PathCHART, the existing standards from 2023 will remain unchanged in these lists.
- For cases diagnosed January 1, 2024, and forward, the CPC SMVLs serve as the basis for the Primary Site, Morphology-Type, Beh ICDO3 2024 (N7040) edit, which checks for valid, unlikely and impossible site, histology, and behavior code combinations.
Standards Released October 2025
- V2024A_V2025A_V2026_CPC_SMVL.xlsx (XLSX, 8.7 MB)
- V2024A_V2025A_V2026_CPC_SMVL.xml (XML, 22.2 MB)
- V2024A_V2025A_V2026_CPC_SMVL.csv (CSV, 6.8 MB)
- V2024A_V2025A_V2026_CPC_SMVL.json (JSON, 33.8 MB)
- V2024A_V2025A_V2026_CPC_SMVL_Release_Notes.docx (DOCX, 42 KB)
For the 2024 and 2025 CPC SMVLs, second versions (V2024A and V2025A) are included in the current October 2025 release file along with the 2026 standards (V2026) as separate columns for each implementation year. This version, released in October 2025, is V2024A_V2025A_V2026. Details about changes to CPC SMVL file generation can be found in the V2024A_V2025A_V2026 CPC SMVL Release Notes (DOCX, 42 KB). Head and neck sites were the only primary tumor sites reviewed for the V2026 CPC SMVL.
Archived Tumor Site-Morphology Standards
2025 Tumor Site-Morphology Standards
- 2025_CPC_SMVL_07122024.xlsx (XLSX, 4.9 MB)
- 2025_CPC_SMVL_07122024.xml (XML, 28.6 MB)
- 2025_CPC_SMVL_07122024.csv (CSV, 4.5 MB)
- 2025_CPC_SMVL_07122024.json (JSON, 29.5 MB)
- 2025_CPC_SMVL_v1.0_Release_Notes.docx (DOCX, 40 KB)
The New Impossible Unlikely Valid 2025 file lists the tumor site-morphology combinations for which validity status changed after CPC expert pathologist review of the sites/organ systems reviewed for implementation for cases diagnosed January 1, 2025 and forward. There are two worksheets included in this Excel file: 2025 Changes in Validity Status and Site_Codes.
2025 Changes in Validity Status Worksheet: These are the newly Valid, Impossible or Unlikely entities by CPC-specific site group. See the Site_Codes worksheet for what ICD-O-3 topography codes correspond to each site group (see Site_Codes below).
| Column Header | Content Description | Comments on Values |
| Site Group | Tumor site group | See Site_Codes worksheet |
| Prior to CPC Review | Validity status for site and morphology code combination prior to CPC Pathologist review | New WHO Code Valid Impossible Unlikely |
| After CPC Review | CPC Validity Status for site and morphology code combination after CPC Pathologist review | Valid Impossible Unlikely |
| Morphology | ICD-O-3.2 morphology code | “New WHO Code” corresponds to new entities included in the WHO Classification of Tumours series 5th editions adopted for use by North America, and therefore do not have an ICD-O-3.2 morphology code |
| ICD-O-3.2 Preferred Term | ICD-O-3.2 preferred term | WHO terms are included for New WHO Codes |
Site_Codes: These are the ICD-O-3 topography codes that correspond to each Cancer PathCHART-specific site group. The Cancer PathCHART-specific site groups were developed to facilitate pathologist review of site-morphology combinations. Important Note: These groupings were developed exclusively for the Cancer PathCHART review process and should not be used in any other capacities, such as for cancer trends.
2024 Tumor Site-Morphology Standards
- 2024_CPC_SMVL_08292023.xlsx (XLSX, 4.3 MB)
- 2024_CPC_SMVL_08292023.xml (XML, 25.4 MB)
- 2024_CPC_SMVL_08292023.csv (CSV, 4.0 MB)
- 2024_CPC_SMVL_08292023.json (JSON, 19.2 MB)
- 2024_CPC_SMVL_v1.0_Release_Notes.docx (DOCX, 42 KB)
The New Impossible Unlikely Valid 2024 file lists the tumor site-morphology combinations for which validity status changed after CPC expert pathologist review of the sites/organ systems reviewed for implementation for cases diagnosed January 1, 2024 and forward. There are two worksheets included in this Excel file: 2024 Changes in Validity Status and Site_Codes.
2024 Changes in Validity Status Worksheet: These are the newly Valid, Impossible or Unlikely entities by CPC-specific site group. See the Site_Codes worksheet for what ICD-O-3 topography codes correspond to each site group (see Site_Codes below).
| Column Header | Content Description | Comments on Values |
| Site Group | Tumor site group | See Site_Codes worksheet |
| Prior to CPC Review | Validity status for site and morphology code combination prior to CPC Pathologist review | New WHO Code Valid Impossible Unlikely |
| After CPC Review | CPC Validity Status for site and morphology code combination after CPC Pathologist review | Valid Impossible Unlikely |
| Morphology | ICD-O-3.2 morphology code | “New WHO Code” corresponds to new entities included in the WHO Classification of Tumours series 5th editions adopted for use by North America, and therefore do not have an ICD-O-3.2 morphology code |
| ICD-O-3.2 Preferred Term | ICD-O-3.2 preferred term | WHO terms are included for New WHO Codes |
Site_Codes: These are the ICD-O-3 topography codes that correspond to each Cancer PathCHART-specific site group. The Cancer PathCHART-specific site groups were developed to facilitate pathologist review of site-morphology combinations. Important Note: These groupings were developed exclusively for the Cancer PathCHART review process and should not be used in any other capacities, such as for cancer trends.
Sites Reviewed by Implementation Year
Tumor Sites Not Yet Reviewed
| Organ System | Primary Tumor Site(s) |
|---|---|
| Pending Sites | Skin, Eye and Orbit, Thyroid Gland, Adrenal Gland, Pituitary, Craniopharyngeal Duct, Pineal Gland, Parathyroid Gland, Carotid body, Aortic Body and Other Paraganglia |
2026
| Organ System | Primary Tumor Site(s) |
|---|---|
| Head and Neck | Lip, Oral Cavity and Mobile Tongue, Gingiva, Major Salivary Glands, Nasopharynx, Oropharynx, Branchial cleft, Nasal Cavity and Paranasal Sinuses, Middle Ear, Larynx and Hypopharynx, Pharynx including Waldeyer Ring, Trachea and Upper Respiratory |
2025
| Organ System | Primary Tumor Site(s) |
|---|---|
| Respiratory Tract | Lung and Bronchus; Pleura |
| Thorax | Thymus; Mediastinal Space |
| Soft Tissue | Peripheral Nerves and Autonomic Nervous System; Retroperitoneum; Heart and Pericardium |
| Male Genital System | Epididymis, Paratesticular and Spermatic cord; Testis* |
| Urinary System | Urethra; Urothelial Sites; Paraurethral Gland; Kidney* |
| CNS | Cerebral Hemispheres; Cerebellum; Brainstem; Ventricles; Meninges; Cranial Nerves; Spinal Cord |
2024
| Organ System | Primary Tumor Site(s) |
|---|---|
| Bone & Soft Tissue | Bones & Joints; Connective, Subcutaneous & Other Soft Tissue |
| Breast | Breast |
| Digestive | Ampulla of Vater; Anus; Appendix; Biliary System; Colon & Rectum; Esophagus; Gallbladder; Liver; Pancreas; Small Intestine; Stomach |
| Female Genital | Cervix; Endometrium; Fallopian Tube; Myometrium; Ovary; Vagina; Vulva, Adnexa & Other Female Genital; Placenta |
| Male Genital | Penis; Prostate; Testis* |
| Urinary | Kidney* |
* Morphologies not reviewed for the tumor site for implementation in 2024 were reviewed for implementation in 2025.
CPC*Search Tool
This Search Interface for 2024 allows for searches of histology and behavior codes, morphology terms, and tumor site combinations in the 2024 CPC SMVL.
Visit NowIf you have any questions about Cancer PathCHART, Ask a SEER Registrar.
